ALEC Quote, Financials, Valuation and Earnings

Geron has a net margin of -3.82% compared to Alector's net margin of -53.33%. Alector's return on equity of -83.91% beat Geron's return on equity of -59.29%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 314.01%. On the other hand Geron has an analysts' consensus of $4.13 which suggests that it could grow by 214.89%. Given that Alector has higher upside potential than Geron, analysts believe Alector is more attractive than Geron.

Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are larger than Geron quarterly revenues of $47.5M. Alector's net income of -$2.1M is higher than Geron's net income of -$25.4M. Notably, Alector's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.98x versus 10.99x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -3.82% compared to Alector's net margin of -53.36%. Alector's return on equity of -83.91% beat Madrigal Pharmaceuticals's return on equity of -49.57%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 314.01%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $421.93 which suggests that it could grow by 41.2%. Given that Alector has higher upside potential than Madrigal Pharmaceuticals, analysts believe Alector is more attractive than Madrigal Pharmaceuticals.

Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Alector's net income of -$2.1M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Alector's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.98x versus 20.52x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -3.82% compared to Alector's net margin of -103.5%. Alector's return on equity of -83.91% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 314.01%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $79.00 which suggests that it could grow by 21.2%. Given that Alector has higher upside potential than Rhythm Pharmaceuticals, analysts believe Alector is more attractive than Rhythm Pharmaceuticals.

Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.362, suggesting its more volatile than the S&P 500 by 136.233%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Alector's net income of -$2.1M is higher than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Alector's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.98x versus 30.29x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -3.82% compared to Alector's net margin of 40.56%. Alector's return on equity of -83.91% beat United Therapeutics's return on equity of 19.92%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 314.01%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 26.48%. Given that Alector has higher upside potential than United Therapeutics, analysts believe Alector is more attractive than United Therapeutics.

Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Alector's net income of -$2.1M is lower than United Therapeutics's net income of $322.2M. Notably, Alector's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.98x versus 4.95x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.